TOXIC EPIDERMAL NECROLYSIS
Clinical trials for TOXIC EPIDERMAL NECROLYSIS explained in plain language.
Never miss a new study
Get alerted when new TOXIC EPIDERMAL NECROLYSIS trials appear
Sign up with your email to follow new studies for TOXIC EPIDERMAL NECROLYSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a white blood cell booster heal a rare skin emergency?
Disease control CompletedThis study tested whether G-CSF (a drug that boosts white blood cells) can help heal toxic epidermal necrolysis, a rare but severe skin reaction. Ten patients were randomly assigned to receive G-CSF or a placebo for five days. Researchers measured how fast the skin healed and loo…
Matched conditions: TOXIC EPIDERMAL NECROLYSIS
Phase: PHASE4 • Sponsor: University of Liege • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Arthritis drug shows promise for rare, Life-Threatening skin conditions
Disease control CompletedThis pilot study tested the drug tofacitinib (XELJANZ) in 20 adults with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), rare and severe skin reactions often caused by medications. The main goal was to see how quickly the skin healed completely. Researchers al…
Matched conditions: TOXIC EPIDERMAL NECROLYSIS
Phase: NA • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:13 UTC